IP Australia has issued a consultation paper on implementing the TRIPS protocol.
The TRIPS protocol is the modification (or is that clarification?) of TRIPS obligations to improve the availability of “crisis” pharmaceuticals in least developed and developing countries. From the discussion paper:
The TRIPS Protocol seeks to address this problem by amending the TRIPS Agreement to permit WTO members to issue compulsory licences to produce patented pharmaceutical products for export to least-developed and developing countries. The main features of the Protocol are:
• Licences may only be issued for products of the pharmaceutical sector needed to address public health concerns.
• Countries eligible to import pharmaceuticals under the system comprise any least-developed WTO country or any other WTO country that has notified the TRIPS Council.
• Importing countries are obliged to provide the TRIPS Council with details such as the names and quantities of the products needed and whether they need to issue a compulsory licence in their own country.
• Exporting countries are obliged to notify the TRIPS Council of a range of details and ensure that importing countries have done the same.
• Both importers and exporters must have in place anti-diversion measures to ensure the products produced under the system reach the intended market and are not re-exported.
Read the paper here (pdf).
Submissions due by 4 June 2010.
Apparently those of you out there doing Madrid Protocol filings are grumbling with discontent.
IPKat reports on the LinkedIn user group breakfast at INTA and the formation of a lobby group to get things done.
The group is a moderated Google group so you have to apply via email to join. Go direct here or, if you’re unfamiliar with Google groups (you will need to sign up for a “free” Google account) IPKat has the email details here.